BG106507A - AMINO SUBSTITUTED PYRAZOLO[1,5,-a]-1,5-PYRAMIDINES AND PYRAZOLO[1,5-a]-1,3,5-TRIAZINES - Google Patents
AMINO SUBSTITUTED PYRAZOLO[1,5,-a]-1,5-PYRAMIDINES AND PYRAZOLO[1,5-a]-1,3,5-TRIAZINESInfo
- Publication number
- BG106507A BG106507A BG106507A BG10650702A BG106507A BG 106507 A BG106507 A BG 106507A BG 106507 A BG106507 A BG 106507A BG 10650702 A BG10650702 A BG 10650702A BG 106507 A BG106507 A BG 106507A
- Authority
- BG
- Bulgaria
- Prior art keywords
- pyrazolo
- disorders
- compounds
- pyramidines
- triazines
- Prior art date
Links
Classifications
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D487/00—Heterocyclic compounds containing nitrogen atoms as the only ring hetero atoms in the condensed system, not provided for by groups C07D451/00 - C07D477/00
- C07D487/02—Heterocyclic compounds containing nitrogen atoms as the only ring hetero atoms in the condensed system, not provided for by groups C07D451/00 - C07D477/00 in which the condensed system contains two hetero rings
- C07D487/04—Ortho-condensed systems
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P1/00—Drugs for disorders of the alimentary tract or the digestive system
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P1/00—Drugs for disorders of the alimentary tract or the digestive system
- A61P1/12—Antidiarrhoeals
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P11/00—Drugs for disorders of the respiratory system
- A61P11/02—Nasal agents, e.g. decongestants
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P15/00—Drugs for genital or sexual disorders; Contraceptives
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P25/00—Drugs for disorders of the nervous system
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P25/00—Drugs for disorders of the nervous system
- A61P25/02—Drugs for disorders of the nervous system for peripheral neuropathies
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P25/00—Drugs for disorders of the nervous system
- A61P25/04—Centrally acting analgesics, e.g. opioids
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P25/00—Drugs for disorders of the nervous system
- A61P25/06—Antimigraine agents
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P25/00—Drugs for disorders of the nervous system
- A61P25/08—Antiepileptics; Anticonvulsants
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P25/00—Drugs for disorders of the nervous system
- A61P25/20—Hypnotics; Sedatives
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P25/00—Drugs for disorders of the nervous system
- A61P25/22—Anxiolytics
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P25/00—Drugs for disorders of the nervous system
- A61P25/24—Antidepressants
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P25/00—Drugs for disorders of the nervous system
- A61P25/28—Drugs for disorders of the nervous system for treating neurodegenerative disorders of the central nervous system, e.g. nootropic agents, cognition enhancers, drugs for treating Alzheimer's disease or other forms of dementia
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P3/00—Drugs for disorders of the metabolism
- A61P3/04—Anorexiants; Antiobesity agents
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P3/00—Drugs for disorders of the metabolism
- A61P3/06—Antihyperlipidemics
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P3/00—Drugs for disorders of the metabolism
- A61P3/08—Drugs for disorders of the metabolism for glucose homeostasis
- A61P3/10—Drugs for disorders of the metabolism for glucose homeostasis for hyperglycaemia, e.g. antidiabetics
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P7/00—Drugs for disorders of the blood or the extracellular fluid
- A61P7/04—Antihaemorrhagics; Procoagulants; Haemostatic agents; Antifibrinolytic agents
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P9/00—Drugs for disorders of the cardiovascular system
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P9/00—Drugs for disorders of the cardiovascular system
- A61P9/04—Inotropic agents, i.e. stimulants of cardiac contraction; Drugs for heart failure
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P9/00—Drugs for disorders of the cardiovascular system
- A61P9/10—Drugs for disorders of the cardiovascular system for treating ischaemic or atherosclerotic diseases, e.g. antianginal drugs, coronary vasodilators, drugs for myocardial infarction, retinopathy, cerebrovascula insufficiency, renal arteriosclerosis
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P9/00—Drugs for disorders of the cardiovascular system
- A61P9/12—Antihypertensives
-
- G—PHYSICS
- G01—MEASURING; TESTING
- G01N—INVESTIGATING OR ANALYSING MATERIALS BY DETERMINING THEIR CHEMICAL OR PHYSICAL PROPERTIES
- G01N2333/00—Assays involving biological materials from specific organisms or of a specific nature
- G01N2333/435—Assays involving biological materials from specific organisms or of a specific nature from animals; from humans
- G01N2333/575—Hormones
- G01N2333/5755—Neuropeptide Y
-
- G—PHYSICS
- G01—MEASURING; TESTING
- G01N—INVESTIGATING OR ANALYSING MATERIALS BY DETERMINING THEIR CHEMICAL OR PHYSICAL PROPERTIES
- G01N2333/00—Assays involving biological materials from specific organisms or of a specific nature
- G01N2333/435—Assays involving biological materials from specific organisms or of a specific nature from animals; from humans
- G01N2333/705—Assays involving receptors, cell surface antigens or cell surface determinants
- G01N2333/70571—Assays involving receptors, cell surface antigens or cell surface determinants for neuromediators, e.g. serotonin receptor, dopamine receptor
Landscapes
- Health & Medical Sciences (AREA)
- Chemical & Material Sciences (AREA)
- Organic Chemistry (AREA)
- Engineering & Computer Science (AREA)
- Bioinformatics & Cheminformatics (AREA)
- Life Sciences & Earth Sciences (AREA)
- Public Health (AREA)
- General Chemical & Material Sciences (AREA)
- Medicinal Chemistry (AREA)
- Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
- Veterinary Medicine (AREA)
- Pharmacology & Pharmacy (AREA)
- Chemical Kinetics & Catalysis (AREA)
- Animal Behavior & Ethology (AREA)
- General Health & Medical Sciences (AREA)
- Neurosurgery (AREA)
- Neurology (AREA)
- Biomedical Technology (AREA)
- Diabetes (AREA)
- Cardiology (AREA)
- Hematology (AREA)
- Heart & Thoracic Surgery (AREA)
- Pain & Pain Management (AREA)
- Obesity (AREA)
- Hospice & Palliative Care (AREA)
- Psychiatry (AREA)
- Endocrinology (AREA)
- Anesthesiology (AREA)
- Emergency Medicine (AREA)
- Vascular Medicine (AREA)
- Urology & Nephrology (AREA)
- Child & Adolescent Psychology (AREA)
- Otolaryngology (AREA)
- Pulmonology (AREA)
- Reproductive Health (AREA)
- Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
- Nitrogen Condensed Heterocyclic Rings (AREA)
- Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
- Acyclic And Carbocyclic Compounds In Medicinal Compositions (AREA)
- Investigating Or Analysing Biological Materials (AREA)
Applications Claiming Priority (2)
Application Number | Priority Date | Filing Date | Title |
---|---|---|---|
US15686899P | 1999-09-30 | 1999-09-30 | |
PCT/US2000/026885 WO2001023388A2 (en) | 1999-09-30 | 2000-09-29 | AMINO SUBSTITUTED PYRAZOLO[1,5,-a]-1,5-PYRIMIDINES AND PYRAZOLO[1,5-a]-1,3,5-TRIAZINES |
Publications (1)
Publication Number | Publication Date |
---|---|
BG106507A true BG106507A (en) | 2002-12-29 |
Family
ID=22561433
Family Applications (1)
Application Number | Title | Priority Date | Filing Date |
---|---|---|---|
BG106507A BG106507A (en) | 1999-09-30 | 2002-03-11 | AMINO SUBSTITUTED PYRAZOLO[1,5,-a]-1,5-PYRAMIDINES AND PYRAZOLO[1,5-a]-1,3,5-TRIAZINES |
Country Status (21)
Country | Link |
---|---|
US (1) | US6476038B1 (hu) |
EP (1) | EP1218381B1 (hu) |
JP (2) | JP2003510326A (hu) |
KR (1) | KR20020047201A (hu) |
CN (1) | CN1377355A (hu) |
AT (1) | ATE347553T1 (hu) |
AU (1) | AU7737900A (hu) |
BG (1) | BG106507A (hu) |
CA (1) | CA2379633C (hu) |
CZ (1) | CZ20021089A3 (hu) |
DE (1) | DE60032249T2 (hu) |
EA (1) | EA200200421A1 (hu) |
ES (1) | ES2277855T3 (hu) |
HU (1) | HUP0203131A3 (hu) |
IL (1) | IL148904A0 (hu) |
NO (1) | NO20021357L (hu) |
OA (1) | OA12049A (hu) |
PL (1) | PL354982A1 (hu) |
WO (1) | WO2001023388A2 (hu) |
YU (1) | YU23602A (hu) |
ZA (1) | ZA200202517B (hu) |
Families Citing this family (83)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
US6472528B1 (en) * | 1999-08-10 | 2002-10-29 | Neurocrine Biosciences, Inc. | Synthesis of substituted pyrazolopyrimidines |
HUP0202678A3 (en) | 1999-09-30 | 2004-06-28 | Pfizer | Certain alkylene diamine-substituted pyrazolo[1,5,-a]-1,5-pyrimidines and pyrazolo[1,5-a]-1,3,5-triazines, pharmaceutical compositions containing them and their use |
WO2003076441A1 (en) | 2002-03-07 | 2003-09-18 | Smithkline Beecham Corporation | Pyrazolopyrimidine and pyrazolotriazine derivatives and pharmaceutical compositions containing them |
US7105526B2 (en) | 2002-06-28 | 2006-09-12 | Banyu Pharmaceuticals Co., Ltd. | Benzimidazole derivatives |
FR2842809A1 (fr) * | 2002-07-26 | 2004-01-30 | Greenpharma Sas | NOUVELLES PYRAZOLO[1,5-a]-1,3,5-TRIAZINES SUBSTITUEES ET LEURS ANALOGUES, COMPOSITIONS PHARMACEUTIQUES LES CONTENANT, UTILISATION A TITRE DE MEDICAMENT ET PROCEDES POUR LEUR PREPARATION |
US7196078B2 (en) | 2002-09-04 | 2007-03-27 | Schering Corpoartion | Trisubstituted and tetrasubstituted pyrazolopyrimidines as cyclin dependent kinase inhibitors |
ATE374766T1 (de) | 2003-01-14 | 2007-10-15 | Arena Pharm Inc | 1,2,3-trisubstituierte aryl- und heteroarylderivate als modulatoren des metabolismus zur vorbeugung und behandlung von metabolismus-bedingten krankheiten wie diabetes oder hyperglykämie |
US7772188B2 (en) | 2003-01-28 | 2010-08-10 | Ironwood Pharmaceuticals, Inc. | Methods and compositions for the treatment of gastrointestinal disorders |
US7329658B2 (en) * | 2003-02-06 | 2008-02-12 | Pfizer Inc | Cannabinoid receptor ligands and uses thereof |
US7176210B2 (en) * | 2003-02-10 | 2007-02-13 | Pfizer Inc. | Cannabinoid receptor ligands and uses thereof |
GEP20084329B (en) | 2003-04-29 | 2008-03-25 | Pfizer Ltd | 5,7-diaminopyrazolo [4,3-d] pyrimidines useful in the treatment of hypertension |
AU2004257267B2 (en) * | 2003-07-14 | 2009-12-03 | Arena Pharmaceuticals,Inc | Fused-aryl and heteroaryl derivatives as modulators of metabolism and the prophylaxis and treatment of disorders related thereto |
CN1902177A (zh) | 2003-09-22 | 2007-01-24 | 万有制药株式会社 | 新哌啶衍生物 |
US7153961B2 (en) | 2003-11-25 | 2006-12-26 | Bristol-Myers Squibb Pharma Co. | Salt and crystalline form thereof of a corticotropin releasing factor receptor antagonist |
US7208596B2 (en) | 2003-11-25 | 2007-04-24 | Bristol-Myers Squibb Pharma Company | Processes for the preparation of pyrazolo[1,5-a]-1,3,5-triazines and intermediates thereof |
EP1697369A1 (en) * | 2003-12-22 | 2006-09-06 | SB Pharmco Puerto Rico Inc | Crf receptor antagonists and methods relating thereto |
BRPI0417943A (pt) | 2003-12-22 | 2007-04-17 | Sb Pharmco Inc | antagonistas de receptor de crf e métodos relacionados para essa finalidade |
WO2005097127A2 (en) | 2004-04-02 | 2005-10-20 | Merck & Co., Inc. | Method of treating men with metabolic and anthropometric disorders |
GB0519957D0 (en) * | 2005-09-30 | 2005-11-09 | Sb Pharmco Inc | Chemical compound |
BRPI0518241A (pt) | 2004-11-01 | 2008-04-22 | Amylin Pharmaceuticals Inc | métodos para tratar obesidade e doenças e distúrbios relacionados à obesidade |
WO2006068954A2 (en) * | 2004-12-21 | 2006-06-29 | Schering Corporation | PYRAZOLO[1,5-A]PYRIMIDINE ADENOSINE A2a RECEPTOR ANTAGONISTS |
US7737155B2 (en) | 2005-05-17 | 2010-06-15 | Schering Corporation | Nitrogen-containing heterocyclic compounds and methods of use thereof |
BRPI0610580B8 (pt) | 2005-05-30 | 2021-05-25 | Banyu Pharma Co Ltd | composto derivado de piperidina |
EP1910409A2 (en) | 2005-06-23 | 2008-04-16 | Statens Serum Institut | Tuberculosis vaccines comprising antigens expressed during the latent infection phase |
AU2006277253A1 (en) | 2005-08-10 | 2007-02-15 | Msd K.K. | Pyridone compound |
BRPI0614649A2 (pt) | 2005-08-11 | 2011-04-12 | Amylin Pharmaceuticals Inc | polipeptìdeos hìbridos com propriedades selecionáveis |
AU2006279680B2 (en) | 2005-08-11 | 2012-12-06 | Amylin Pharmaceuticals, Llc | Hybrid polypeptides with selectable properties |
AU2006282260A1 (en) | 2005-08-24 | 2007-03-01 | Msd K.K. | Phenylpyridone derivative |
JPWO2007029847A1 (ja) | 2005-09-07 | 2009-03-19 | 萬有製薬株式会社 | 二環性芳香族置換ピリドン誘導体 |
AU2006297443B2 (en) | 2005-09-29 | 2010-08-12 | Merck Sharp & Dohme Corp. | Acylated spiropiperidine derivatives as melanocortin-4 receptor modulators |
CN101291662A (zh) | 2005-10-21 | 2008-10-22 | 诺瓦提斯公司 | 肾素抑制剂和抗血脂异常剂和/或抗肥胖剂的组合 |
WO2007049798A1 (ja) | 2005-10-27 | 2007-05-03 | Banyu Pharmaceutical Co., Ltd. | 新規ベンゾオキサチイン誘導体 |
NZ568292A (en) | 2005-11-10 | 2011-08-26 | Msd Kk | Spiro[cyclohexane-1,1'-(3'H)-4'-azaisobenzofuran]-4-carboxamide derivatives |
US8030304B2 (en) | 2006-09-20 | 2011-10-04 | Eli Lilly And Company | Thiazole pyrazolopyrimidines CRF1 receptor antagonists |
MX2009003098A (es) * | 2006-09-20 | 2009-04-01 | Lilly Co Eli | Compuestos de tiofen pirazolopirimidina. |
EP2083831B1 (en) | 2006-09-22 | 2013-12-25 | Merck Sharp & Dohme Corp. | Method of treatment using fatty acid synthesis inhibitors |
JPWO2008038692A1 (ja) | 2006-09-28 | 2010-01-28 | 萬有製薬株式会社 | ジアリールケチミン誘導体 |
AU2008233662B2 (en) | 2007-04-02 | 2012-08-23 | Msd K.K. | Indoledione derivative |
EA020466B1 (ru) | 2007-06-04 | 2014-11-28 | Синерджи Фармасьютикалз Инк. | Агонисты гуанилатциклазы, пригодные для лечения желудочно-кишечных нарушений, воспаления, рака и других заболеваний |
US8969514B2 (en) | 2007-06-04 | 2015-03-03 | Synergy Pharmaceuticals, Inc. | Agonists of guanylate cyclase useful for the treatment of hypercholesterolemia, atherosclerosis, coronary heart disease, gallstone, obesity and other cardiovascular diseases |
CA2689667A1 (en) * | 2007-06-07 | 2008-12-18 | Schering Corporation | Synthesis of substituted-3-aminopyrazoles |
AU2009220605A1 (en) | 2008-03-06 | 2009-09-11 | Msd K.K. | Alkylaminopyridine derivative |
AU2009229860A1 (en) | 2008-03-28 | 2009-10-01 | Msd K.K. | Diarylmethylamide derivative having antagonistic activity on melanin-concentrating hormone receptor |
EP2810951B1 (en) | 2008-06-04 | 2017-03-15 | Synergy Pharmaceuticals Inc. | Agonists of guanylate cyclase useful for the treatment of gastrointestinal disorders, inflammation, cancer and other disorders |
US20110071129A1 (en) | 2008-06-19 | 2011-03-24 | Makoto Ando | Spirodiamine-diaryl ketoxime derivative |
US20100015171A1 (en) | 2008-07-15 | 2010-01-21 | Statens Serum Institute | Vaccines comprising tb 10.4 |
ES2624828T3 (es) | 2008-07-16 | 2017-07-17 | Synergy Pharmaceuticals Inc. | Agonistas de la guanilato ciclasa útiles para el tratamiento de trastornos gastrointestinales, inflamación, cáncer y otros |
JPWO2010013595A1 (ja) | 2008-07-30 | 2012-01-12 | Msd株式会社 | 5員−5員又は5員−6員縮環シクロアルキルアミン誘導体 |
WO2010047982A1 (en) | 2008-10-22 | 2010-04-29 | Merck Sharp & Dohme Corp. | Novel cyclic benzimidazole derivatives useful anti-diabetic agents |
PE20110852A1 (es) | 2008-10-30 | 2011-11-25 | Merck Sharp & Dohme | Antagonistas del receptor de orexina de isonicotinamida |
CA2741672A1 (en) | 2008-10-31 | 2010-05-06 | Merck Sharp & Dohme Corp. | Novel cyclic benzimidazole derivatives useful anti-diabetic agents |
EP2379562A1 (en) | 2008-12-16 | 2011-10-26 | Schering Corporation | Bicyclic pyranone derivatives as nicotinic acid receptor agonists |
WO2010075068A1 (en) | 2008-12-16 | 2010-07-01 | Schering Corporation | Pyridopyrimidine derivatives and methods of use thereof |
AU2011218830B2 (en) | 2010-02-25 | 2014-07-24 | Merck Sharp & Dohme Corp. | Novel cyclic benzimidazole derivatives useful anti-diabetic agents |
US9616097B2 (en) | 2010-09-15 | 2017-04-11 | Synergy Pharmaceuticals, Inc. | Formulations of guanylate cyclase C agonists and methods of use |
CA2812061A1 (en) | 2010-09-22 | 2012-03-29 | Arena Pharmaceuticals, Inc. | Modulators of the gpr119 receptor and the treatment of disorders related thereto |
EP3243385B1 (en) | 2011-02-25 | 2021-01-13 | Merck Sharp & Dohme Corp. | Novel cyclic azabenzimidazole derivatives useful as anti-diabetic agents |
AR088352A1 (es) | 2011-10-19 | 2014-05-28 | Merck Sharp & Dohme | Antagonistas del receptor de 2-piridiloxi-4-nitrilo orexina |
JP2015525782A (ja) | 2012-08-02 | 2015-09-07 | メルク・シャープ・アンド・ドーム・コーポレーションMerck Sharp & Dohme Corp. | 抗糖尿病性三環式化合物 |
WO2014075168A1 (en) | 2012-11-16 | 2014-05-22 | University Health Network | Pyrazolopyrimidine compounds |
CN104994848A (zh) | 2013-02-22 | 2015-10-21 | 默沙东公司 | 抗糖尿病二环化合物 |
WO2014139388A1 (en) | 2013-03-14 | 2014-09-18 | Merck Sharp & Dohme Corp. | Novel indole derivatives useful as anti-diabetic agents |
CA2905435A1 (en) | 2013-03-15 | 2014-09-25 | Synergy Pharmaceuticals Inc. | Compositions useful for the treatment of gastrointestinal disorders |
CA2905438A1 (en) | 2013-03-15 | 2014-09-25 | Synergy Pharmaceuticals Inc. | Agonists of guanylate cyclase and their uses |
PT3004138T (pt) | 2013-06-05 | 2024-06-18 | Bausch Health Ireland Ltd | Agonistas ultrapuros de guanilato ciclase c, método de produção e utilização dos mesmos |
WO2015051496A1 (en) | 2013-10-08 | 2015-04-16 | Merck Sharp & Dohme Corp. | Antidiabetic tricyclic compounds |
CA2959208C (en) | 2014-08-29 | 2023-09-19 | Tes Pharma S.R.L. | Pyrimidine derivatives and their use as inhibitors of alpha-amino-beta-carboxymuconate-epsilon-semialdehyde decarboxylase |
CN107405332A (zh) | 2015-01-06 | 2017-11-28 | 艾尼纳制药公司 | 治疗与s1p1受体有关的病症的方法 |
CA3002551A1 (en) | 2015-06-22 | 2016-12-29 | Arena Pharmaceuticals, Inc. | Crystalline l-arginine salt of (r)-2-(7-(4-cyclopentyl-3-(trifluoromethyl)benzyloxy)-1,2,3,4-tetrahydrocyclo-penta[b]indol-3-yl)acetic acid(com pound 1)for use in s1p1 receptor-associated disorders |
EP3507290A1 (en) | 2016-08-31 | 2019-07-10 | Agios Pharmaceuticals, Inc. | Inhibitors of cellular metabolic processes |
EP3526199B1 (en) | 2016-10-14 | 2022-04-13 | Tes Pharma S.r.l. | Inhibitors of alpha-amino-beta-carboxymuconic acid semialdehyde decarboxylase |
US11072602B2 (en) | 2016-12-06 | 2021-07-27 | Merck Sharp & Dohme Corp. | Antidiabetic heterocyclic compounds |
US10968232B2 (en) | 2016-12-20 | 2021-04-06 | Merck Sharp & Dohme Corp. | Antidiabetic spirochroman compounds |
CN110520124A (zh) | 2017-02-16 | 2019-11-29 | 艾尼纳制药公司 | 用于治疗原发性胆汁性胆管炎的化合物和方法 |
JP7353295B2 (ja) * | 2018-04-10 | 2023-09-29 | バイエル・アクチエンゲゼルシヤフト | 2,6-ジアルキルフェニル酢酸の製造方法 |
EP3873911A4 (en) | 2018-10-30 | 2022-06-22 | Kronos Bio, Inc. | COMPOUNDS, COMPOSITIONS AND METHODS FOR MODULATING CDK9 ACTIVITY |
CA3119509A1 (en) | 2018-11-20 | 2020-05-28 | Tes Pharma S.R.L | Inhibitors of alpha-amino-beta-carboxymuconic acid semialdehyde decarboxxylase |
US11098029B2 (en) | 2019-02-13 | 2021-08-24 | Merck Sharp & Dohme Corp. | 5-alkyl pyrrolidine orexin receptor agonists |
EP4010314B1 (en) | 2019-08-08 | 2024-02-28 | Merck Sharp & Dohme LLC | Heteroaryl pyrrolidine and piperidine orexin receptor agonists |
KR20230043222A (ko) | 2020-08-12 | 2023-03-30 | 스프루스 바이오사이언시스 인코포레이티드 | 다낭성 난소 증후군을 치료하기 위한 방법 및 조성물 |
TW202227417A (zh) | 2020-08-18 | 2022-07-16 | 美商默沙東藥廠 | 雙環庚烷吡咯啶之食慾素受體促效劑 |
US11708372B2 (en) | 2021-11-19 | 2023-07-25 | Spruce Biosciences, Inc. | Crystalline composition of tildacerfont and methods of use and preparation thereof |
CN115304607B (zh) * | 2022-07-06 | 2023-06-27 | 华南农业大学 | 吡唑并嘧啶衍生物的制备方法 |
Family Cites Families (3)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
DK0915880T3 (da) | 1996-07-24 | 2008-02-11 | Bristol Myers Squibb Pharma Co | Azolotriaziner og pyrimidiner |
WO1999007703A1 (en) * | 1997-08-05 | 1999-02-18 | Pfizer Products Inc. | 4-AMINOPYRROLE(3,2-d) PYRIMIDINES AS NEUROPEPTIDE Y RECEPTOR ANTAGONISTS |
US6187777B1 (en) * | 1998-02-06 | 2001-02-13 | Amgen Inc. | Compounds and methods which modulate feeding behavior and related diseases |
-
2000
- 2000-09-29 CN CN00813627A patent/CN1377355A/zh active Pending
- 2000-09-29 YU YU23602A patent/YU23602A/sh unknown
- 2000-09-29 JP JP2001526540A patent/JP2003510326A/ja not_active Ceased
- 2000-09-29 EP EP00967132A patent/EP1218381B1/en not_active Expired - Lifetime
- 2000-09-29 US US09/676,972 patent/US6476038B1/en not_active Expired - Fee Related
- 2000-09-29 DE DE60032249T patent/DE60032249T2/de not_active Expired - Fee Related
- 2000-09-29 HU HU0203131A patent/HUP0203131A3/hu unknown
- 2000-09-29 ES ES00967132T patent/ES2277855T3/es not_active Expired - Lifetime
- 2000-09-29 AU AU77379/00A patent/AU7737900A/en not_active Abandoned
- 2000-09-29 PL PL00354982A patent/PL354982A1/xx not_active Application Discontinuation
- 2000-09-29 IL IL14890400A patent/IL148904A0/xx unknown
- 2000-09-29 CA CA002379633A patent/CA2379633C/en not_active Expired - Fee Related
- 2000-09-29 AT AT00967132T patent/ATE347553T1/de not_active IP Right Cessation
- 2000-09-29 WO PCT/US2000/026885 patent/WO2001023388A2/en active IP Right Grant
- 2000-09-29 EA EA200200421A patent/EA200200421A1/ru unknown
- 2000-09-29 OA OA1200200088A patent/OA12049A/en unknown
- 2000-09-29 KR KR1020027004178A patent/KR20020047201A/ko not_active Application Discontinuation
- 2000-09-29 CZ CZ20021089A patent/CZ20021089A3/cs unknown
-
2002
- 2002-03-11 BG BG106507A patent/BG106507A/xx unknown
- 2002-03-19 NO NO20021357A patent/NO20021357L/no not_active Application Discontinuation
- 2002-03-28 ZA ZA200202517A patent/ZA200202517B/xx unknown
-
2006
- 2006-09-06 JP JP2006241067A patent/JP2007077144A/ja active Pending
Also Published As
Publication number | Publication date |
---|---|
ZA200202517B (en) | 2003-05-28 |
WO2001023388A2 (en) | 2001-04-05 |
JP2003510326A (ja) | 2003-03-18 |
HUP0203131A2 (hu) | 2003-01-28 |
DE60032249D1 (de) | 2007-01-18 |
EA200200421A1 (ru) | 2002-10-31 |
HUP0203131A3 (en) | 2004-06-28 |
US6476038B1 (en) | 2002-11-05 |
OA12049A (en) | 2006-05-02 |
NO20021357L (no) | 2002-05-23 |
AU7737900A (en) | 2001-04-30 |
JP2007077144A (ja) | 2007-03-29 |
CA2379633A1 (en) | 2001-04-05 |
NO20021357D0 (no) | 2002-03-19 |
DE60032249T2 (de) | 2007-07-19 |
YU23602A (sh) | 2004-09-03 |
PL354982A1 (en) | 2004-03-22 |
CA2379633C (en) | 2006-06-20 |
ATE347553T1 (de) | 2006-12-15 |
EP1218381A2 (en) | 2002-07-03 |
CN1377355A (zh) | 2002-10-30 |
CZ20021089A3 (cs) | 2002-11-13 |
KR20020047201A (ko) | 2002-06-21 |
EP1218381B1 (en) | 2006-12-06 |
IL148904A0 (en) | 2002-09-12 |
WO2001023388A3 (en) | 2001-10-18 |
ES2277855T3 (es) | 2007-08-01 |
Similar Documents
Publication | Publication Date | Title |
---|---|---|
BG106507A (en) | AMINO SUBSTITUTED PYRAZOLO[1,5,-a]-1,5-PYRAMIDINES AND PYRAZOLO[1,5-a]-1,3,5-TRIAZINES | |
BG106506A (en) | ALKYLENE DIAMINE-SUBSTITUTED PYRAZOLO[1,5,-a)-1,5-PYRIMIDINES AND PARAZOLO[1,5-a)-1,3,5-TRIAZINES | |
TR199801594A2 (xx) | CCR-3 resept�r antagonistleri. | |
PL370972A1 (en) | 1-alkyl-1-azoniabicyclo (2.2.2) octane carbamate derivatives and their use as muscarinic receptor antagonists | |
BG100946A (en) | New amino acid derivatives, method for their preparation and pharmaceutical compositions containing them | |
EP1109542A4 (en) | NITROSED AND NITROSYLATED ANTAGONISTS OF THE ALPHA ADRENERGIC RECEPTOR, COMPOSITIONS AND USES THEREOF | |
AP2001002088A0 (en) | 4,4-Biarylpiperidine derivatives with opiod receptor activity. | |
MY118163A (en) | Aryl fused azapolycyclic compounds | |
JO2359B1 (en) | Benzathene derivatives as agents for modulation of GABA A receptor | |
IL114599A0 (en) | Substituted pyrimidine compounds their preparation and pharmaceutical compositions containing them | |
IL141997A0 (en) | Novel n-(iminomethyl) amine derivatives, their preparation, their use as medicines and compositions containing them | |
MY122278A (en) | 1,2,3,4,5,6-hexahydroazepino[4,5-b]indoles containing arylsulfones at the 9-position | |
WO2002012224A3 (en) | Bicyclic compounds as h3 receptor ligands | |
ZA200110540B (en) | Novel diphenyl-piperidine derivate. | |
BG108427A (en) | 2,5-diarylpyrazines, 2,5-diarylpyridines and 2,5-diaryl pyrimidines as crf1 receptor modulators | |
AU1667500A (en) | N-(2-phenyl-4-piperidinybutyl)-5,6,7,8-tetrahydro-1-naphthal necarboxamides and their use as neurokinin 1 (nk1) and/or neurokinin 2 (nk2) receptor antagonists | |
HUP0301228A3 (en) | 3-azabicyclo(3.1.0)hexane derivatives having opioid receptor affinity, process for their preparation and pharmaceutical compositions containing them | |
MXPA04000358A (es) | Hexahidroazepino (4,5-g) indoles e indolinas como ligandos del receptor 5-ht. | |
IL145645A0 (en) | N-(2-phenyl-4-amino-butyl)-1-naphthamides as neurokinin-1 receptor antagonists | |
HUP0201710A3 (en) | Biphenyl derivatives as antagonists of the neurokinine-1 receptor, process for producing them and pharmaceutical compositions containing them | |
WO2001068614A3 (en) | 5-substituted arylpyrimidines | |
AU3476599A (en) | Indol-3-yl-cyclohexyl amine derivatives for the treatment of depression (5-ht1 receptor antagonists) | |
HUP0201725A3 (en) | Indoloazepines as vasopressin receptor antagonists, their use, pharmaceutical compositions containing them and process for the preparation thereof | |
WO2001046176A3 (en) | Non peptide tachykinin receptor antagonists | |
PL370114A1 (en) | Bridged bicycle (1,4) benzodiazepine vasopressin receptor antagonists |